Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer

Alan P. Lombard, Chengfei Liu, Cameron M. Armstrong, Leandro S. D'Abronzo, Wei Lou, Hongwu Chen, Marc Dall'Era, Paramita M Ghosh, Christopher P Evans, Allen C Gao

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Castration-resistant prostate cancer remains as an incurable disease. Exploiting DNA damage repair defects via inhibition of poly (ADP-ribose)polymerase (PARP)is becoming an attractive therapeutic option. The TOPARP-A clinical trial demonstrated that the PARP inhibitor olaparib may be an effective strategy for treating prostate cancer. However, several unanswered questions regarding the use of olaparib remain: 1)How do we best stratify patients for olaparib treatment? 2)Where do we place olaparib in the treatment sequence paradigm? 3)Is there cross-resistance between olaparib and currently used therapies? Here, we tested putative cross-resistance between current therapies and olaparib in treatment-resistant castration-resistant prostate cancer models. Docetaxel-resistant cells exhibited robust resistance to olaparib which could be attributed to blunted PARP trapping in response to olaparib treatment. Upregulated ABCB1 mediates cross-resistance between taxanes and olaparib, which can be overcome through decreasing ABCB1 expression or inhibiting ABCB1 using elacridar or enzalutamide. We also show that combining olaparib with enzalutamide is more effective in olaparib-sensitive cells than either single agent. Our results demonstrate that cross-resistance between olaparib and other therapies could blunt response to treatment and highlight the need to develop strategies to maximize olaparib efficacy.

Original languageEnglish (US)
Pages (from-to)871-878
Number of pages8
JournalTranslational Oncology
Volume12
Issue number7
DOIs
StatePublished - Jul 1 2019

Fingerprint

Prostatic Neoplasms
Therapeutics
Poly(ADP-ribose) Polymerases
Castration
docetaxel
olaparib
taxane
Taxoids
DNA Repair
DNA Damage
Clinical Trials

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer. / Lombard, Alan P.; Liu, Chengfei; Armstrong, Cameron M.; D'Abronzo, Leandro S.; Lou, Wei; Chen, Hongwu; Dall'Era, Marc; Ghosh, Paramita M; Evans, Christopher P; Gao, Allen C.

In: Translational Oncology, Vol. 12, No. 7, 01.07.2019, p. 871-878.

Research output: Contribution to journalArticle

Lombard, Alan P. ; Liu, Chengfei ; Armstrong, Cameron M. ; D'Abronzo, Leandro S. ; Lou, Wei ; Chen, Hongwu ; Dall'Era, Marc ; Ghosh, Paramita M ; Evans, Christopher P ; Gao, Allen C. / Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer. In: Translational Oncology. 2019 ; Vol. 12, No. 7. pp. 871-878.
@article{8f60f8b30b3b40148e1f690e0c821fd0,
title = "Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer",
abstract = "Castration-resistant prostate cancer remains as an incurable disease. Exploiting DNA damage repair defects via inhibition of poly (ADP-ribose)polymerase (PARP)is becoming an attractive therapeutic option. The TOPARP-A clinical trial demonstrated that the PARP inhibitor olaparib may be an effective strategy for treating prostate cancer. However, several unanswered questions regarding the use of olaparib remain: 1)How do we best stratify patients for olaparib treatment? 2)Where do we place olaparib in the treatment sequence paradigm? 3)Is there cross-resistance between olaparib and currently used therapies? Here, we tested putative cross-resistance between current therapies and olaparib in treatment-resistant castration-resistant prostate cancer models. Docetaxel-resistant cells exhibited robust resistance to olaparib which could be attributed to blunted PARP trapping in response to olaparib treatment. Upregulated ABCB1 mediates cross-resistance between taxanes and olaparib, which can be overcome through decreasing ABCB1 expression or inhibiting ABCB1 using elacridar or enzalutamide. We also show that combining olaparib with enzalutamide is more effective in olaparib-sensitive cells than either single agent. Our results demonstrate that cross-resistance between olaparib and other therapies could blunt response to treatment and highlight the need to develop strategies to maximize olaparib efficacy.",
author = "Lombard, {Alan P.} and Chengfei Liu and Armstrong, {Cameron M.} and D'Abronzo, {Leandro S.} and Wei Lou and Hongwu Chen and Marc Dall'Era and Ghosh, {Paramita M} and Evans, {Christopher P} and Gao, {Allen C}",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/j.tranon.2019.04.007",
language = "English (US)",
volume = "12",
pages = "871--878",
journal = "Translational Oncology",
issn = "1936-5233",
publisher = "Neoplasia Press",
number = "7",

}

TY - JOUR

T1 - Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer

AU - Lombard, Alan P.

AU - Liu, Chengfei

AU - Armstrong, Cameron M.

AU - D'Abronzo, Leandro S.

AU - Lou, Wei

AU - Chen, Hongwu

AU - Dall'Era, Marc

AU - Ghosh, Paramita M

AU - Evans, Christopher P

AU - Gao, Allen C

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Castration-resistant prostate cancer remains as an incurable disease. Exploiting DNA damage repair defects via inhibition of poly (ADP-ribose)polymerase (PARP)is becoming an attractive therapeutic option. The TOPARP-A clinical trial demonstrated that the PARP inhibitor olaparib may be an effective strategy for treating prostate cancer. However, several unanswered questions regarding the use of olaparib remain: 1)How do we best stratify patients for olaparib treatment? 2)Where do we place olaparib in the treatment sequence paradigm? 3)Is there cross-resistance between olaparib and currently used therapies? Here, we tested putative cross-resistance between current therapies and olaparib in treatment-resistant castration-resistant prostate cancer models. Docetaxel-resistant cells exhibited robust resistance to olaparib which could be attributed to blunted PARP trapping in response to olaparib treatment. Upregulated ABCB1 mediates cross-resistance between taxanes and olaparib, which can be overcome through decreasing ABCB1 expression or inhibiting ABCB1 using elacridar or enzalutamide. We also show that combining olaparib with enzalutamide is more effective in olaparib-sensitive cells than either single agent. Our results demonstrate that cross-resistance between olaparib and other therapies could blunt response to treatment and highlight the need to develop strategies to maximize olaparib efficacy.

AB - Castration-resistant prostate cancer remains as an incurable disease. Exploiting DNA damage repair defects via inhibition of poly (ADP-ribose)polymerase (PARP)is becoming an attractive therapeutic option. The TOPARP-A clinical trial demonstrated that the PARP inhibitor olaparib may be an effective strategy for treating prostate cancer. However, several unanswered questions regarding the use of olaparib remain: 1)How do we best stratify patients for olaparib treatment? 2)Where do we place olaparib in the treatment sequence paradigm? 3)Is there cross-resistance between olaparib and currently used therapies? Here, we tested putative cross-resistance between current therapies and olaparib in treatment-resistant castration-resistant prostate cancer models. Docetaxel-resistant cells exhibited robust resistance to olaparib which could be attributed to blunted PARP trapping in response to olaparib treatment. Upregulated ABCB1 mediates cross-resistance between taxanes and olaparib, which can be overcome through decreasing ABCB1 expression or inhibiting ABCB1 using elacridar or enzalutamide. We also show that combining olaparib with enzalutamide is more effective in olaparib-sensitive cells than either single agent. Our results demonstrate that cross-resistance between olaparib and other therapies could blunt response to treatment and highlight the need to develop strategies to maximize olaparib efficacy.

UR - http://www.scopus.com/inward/record.url?scp=85065146528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065146528&partnerID=8YFLogxK

U2 - 10.1016/j.tranon.2019.04.007

DO - 10.1016/j.tranon.2019.04.007

M3 - Article

AN - SCOPUS:85065146528

VL - 12

SP - 871

EP - 878

JO - Translational Oncology

JF - Translational Oncology

SN - 1936-5233

IS - 7

ER -